Αποτελέσματα αναζήτησης - "лекарственные поражения печени"

1

Academic Journal

Psoriasis and its impact on liver health: What a dermatologist needs to know ; Псориаз и его влияние на здоровье печени: что нужно знать дерматологу

Συγγραφείς: E. V. Denisova, K. V. Katkova, K. T. Plieva, O. V. Zhukova, I. M. Korsunskaya, Е. В. Денисова, К. В. Каткова, К. Т. Плиева, О. В. Жукова, И. М. Корсунская

Πηγή: Meditsinskiy sovet = Medical Council; № 2 (2025); 66-70 ; Медицинский Совет; № 2 (2025); 66-70 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: воспаление, hepatobiliary tract disorders, drug-induced liver injury, ademetionine, inflammation, нарушения гепатобилиарной системы, лекарственные поражения печени, адеметионин

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8950/7779; Freuer D, Linseisen J, Meisinger C. Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study. JAMA Dermatol. 2022;158(11):1262–1268. https://doi.org/10.1001/jamadermatol.2022.3682.; Fraga NA, Oliveira Mde F, Follador I, Rocha Bde O, Rêgo VR. Psoriasis and uveitis: a literature review. An Bras Dermatol. 2012;87(6):877–883. https://doi.org/10.1590/s0365-05962012000600009.; Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. J Am Coll Cardiol. 2021;77(13):1670–1680. https://doi.org/10.1016/j.jacc.2021.02.009.; Соболев ВВ, Саутин МЕ, Пирузян АЛ, Соболева АГ, Корсунская ИМ. Общие механизмы и медиаторы воспаления в развитии атеросклероза и псориаза. Эффективная фармакотерапия. 2017;15(2):16–19. Режим доступа: https://umedp.ru/upload/iblock/d27/psoriaz.pdf.; Halioua B, Chelli C, Misery L, Taieb J, Taieb C. Sleep Disorders and Psoriasis: An Update. Acta Derm Venereol. 2022;102:adv00699. https://doi.org/10.2340/actadv.v102.1991.; Näslund-Koch C, Bojesen SE, Gluud LL, Skov L, Vedel-Krogh S. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals. Front Immunol. 2022;13:1022460. https://doi.org/10.3389/fimmu.2022.1022460.; Kędra K, Janeczko K, Michalik I, Reich A. Sexual Dysfunction in Women and Men with Psoriasis: A Cross-Sectional Questionnaire-Based Study. Medicina. 2022;58(10):1443. https://doi.org/10.3390/medicina58101443.; Hedemann TL, Liu X, Kang CN, Husain MI. Associations between psoriasis and mental illness: an update for clinicians. Gen Hosp Psychiatry. 2022;75:30–37. https://doi.org/10.1016/j.genhosppsych.2022.01.006.; Balak DMW, Piaserico S, Kasujee I. Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies. Psoriasis. 2021;11:151–168. https://doi.org/10.2147/PTT.S342911.; McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci USA. 2012;109(Suppl. 2):17180–17185. https://doi.org/10.1073/pnas.1121254109.; Polenghi MM, Molinari E, Gala C, Guzzi R, Garutti C, Finzi AF. Experience with psoriasis in a psychosomatic dermatology clinic. Acta Derm Venereol Suppl. 1994;186:65–66. https://doi.org/10.2340/000155551866566.; Al-Harbi NO, Nadeem A, Al-Harbi MM, Zoheir KMA, Ansari MA, El-Sherbeeny AM et al. Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model. Immunobiology. 2017;222(2):128–136. https://doi.org/10.1016/j.imbio.2016.10.013.; Mancini S, Amorotti E, Vecchio S, de Leon MP, Roncucci L. Infliximab-related hepatitis: Discussion of a case and review of the literature. Internal and Emergency Medicine. 2010;5(3):193–200. https://doi.org/10.1007/s11739-009-0342-4.; Tula E, Ergun T, Seckin D, Ozgen Z, Avsar E. Psoriasis and the liver: problems, causes and course. Australas J Dermatol. 2017;58(3):194–199. https://doi.org/10.1111/ajd.12460.; Helliwell PS, Taylor WJ; CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs – comparison of drugs and adverse reactions. J Rheumatol. 2008;35(3):472–476. Available at: https://pubmed.ncbi.nlm.nih.gov/18203324.; Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. Can Med Assoc. J 2005;172(7):899–905. https://doi.org/10.1503/cmaj.045232.; Zhang H, Bernuzzi F, Lleo A, Ma X, Invernizzi P. Therapeutic Potential of IL-17- Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators Inflamm. 2015;2015:436450. https://doi.org/10.1155/2015/436450.436450.; Sakkas LI, Bogdanos DP. Are psoriasis and psoriatic arthritis the same disease? The IL-23/IL-17 axis data. Autoimmun Rev. 2017;16(1):10–15. https://doi.org/10.1016/j.autrev.2016.09.015.; Boström EA, Ekstedt M, Kechagias S, Sjöwall C, Bokarewa MI, Almer S. Resistin is Associated with Breach of Tolerance and Anti-nuclear Antibodies in Patients with Hepatobiliary Inflammation. Scand J Immunol. 2011;74(5):463–470. https://doi.org/10.1111/j.1365-3083.2011.02592.x.; Barak V, Selmi C, Schlesinger M, Blank M, Agmon-Levin N, Kalickman I et al. Serum inflammatory cytokines, complement components, and soluble interleukin 2 receptor in primary biliary cirrhosis. J Autoimmun. 2009;33(3-4): 178–182. https://doi.org/10.1016/j.jaut.2009.09.010.; Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clin Exp Immunol. 2009;157(2):261–270. https://doi.org/10.1111/j.1365-2249.2009.03947.x.; Zhao J, Zhao S, Zhou G, Liang L, Guo X, Mao P et al. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol. 2011;46(4):485–494. https://doi.org/10.3109/00365521.2010.539624.; Bo X, Broome U, Remberger M, Sumitran-Holgersson S. Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis. Gut. 2001;49(1):131–141. https://doi.org/10.1136/gut.49.1.131.; Tobin D, Vuckovic A, Sarris J. Targeting Divergent Pathways in the Nutritional Management of Depression. Nutrients. 2024;16(16):2806. https://doi.org/10.3390/nu16162806.; Finkelstein JD. Methionine Metabolism in Mammals. J Nutr Biochem. 1990;(5):228–237. https://doi.org/10.1016/0955-2863(90)90070-2.; Bottiglieri T, Hyland K, Reynolds EH. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. Drugs. 1994;48(2):137–152. https://doi.org/10.2165/00003495-199448020-00002.; Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol. 1999;30(6):1155–1159. https://doi.org/10.1016/s0168-8278(99)80274-8.; Almasio P, Bortolini M, Pagliaro L, Coltorti M. Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs. 1990;40(Suppl. 3):111–123. https://doi.org/10.2165/00003495-199000403-00011.; Perlamutrov Y, Bakulev A, Korsunskaya I, Orlov E, Bolotnikova N. Ademetionine in Treatment of Drug Induced Liver Injury: an Observational Study in Russian Patients, Receiving Immunosuppressive Therapy for Psoriasis. Int J Pharm Sci Res. 2014;5(12):5163–5169. https://doi.org/10.13040/IJPSR.0975-8232.5(12).5163-69.; Соболев ВВ, Денисова ЕВ, Соболева АГ, Корсунская ИМ, Чекалин ЕВ, Золотаренко АД, Брускин СА. Метилирование генов в CD3+-клетках при псориазе. Российский журнал кожных и венерических болезней. 2013;16(1):40–43. https://doi.org/10.17816/dv36791.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8950
https://doi.org/10.21518/ms2025-043

View record from BASE

2

Academic Journal

ЛЕКАРСТВЕННО-ИНДУЦИРОВАННОЕ ПОРАЖЕНИЕ ПЕЧЕНИ

Συγγραφείς: Умаров Фируз Холмуродович

Πηγή: JOURNAL OF HEALTHCARE AND LIFE-SCIENCE RESEARCH; Vol. 4 No. 4 (2025): Journal of Healthcare and Life-Science Research; 143-150

Θεματικοί όροι: лекарственные поражения печени

Περιγραφή αρχείου: application/pdf

Relation: https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1285/1107; https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1285

Διαθεσιμότητα: https://jhlsr.innovascience.uz/index.php/jhlsr/article/view/1285

View record from BASE

3

Academic Journal

Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19 ; Анализ потребления препаратов с высоким риском развития лекарственного поражения печени при COVID-19

Συγγραφείς: V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva, В. И. Петров, А. Ю. Рязанова, Н. С. Токарева

Συνεισφορές: The study was performed without external funding., Работа выполнена без спонсорской поддержки.

Πηγή: Safety and Risk of Pharmacotherapy; Том 12, № 3 (2024); 268-284 ; Безопасность и риск фармакотерапии; Том 12, № 3 (2024); 268-284 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2024-12-3

Περιγραφή αρχείου: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/396/1221; https://www.risksafety.ru/jour/article/view/396/1047; https://www.risksafety.ru/jour/article/view/396/1049; https://www.risksafety.ru/jour/article/view/396/1053; https://www.risksafety.ru/jour/article/view/396/1056; https://www.risksafety.ru/jour/article/view/396/1064; https://www.risksafety.ru/jour/article/view/396/1061; https://www.risksafety.ru/jour/article/view/396/1070; https://www.risksafety.ru/jour/article/view/396/1071; https://www.risksafety.ru/jour/article/view/396/1086; https://www.risksafety.ru/jour/article/view/396/1090; https://www.risksafety.ru/jour/article/downloadSuppFile/396/475; https://www.risksafety.ru/jour/article/downloadSuppFile/396/481; https://www.risksafety.ru/jour/article/downloadSuppFile/396/483; Xie H, Zhao J, Lian N, Lin S, Xie Q, Zhuo H. Clinical characteristics of non-ICU hospitalized patients with coronavirus disease 2019 and liver injury: a retrospective study. Liver Int. 2020;40(6):1321–6. https://doi.org/10.1111/liv.14449; Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. Clinical features of COVID-19-related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–6. https://doi.org/10.1016/j.cgh.2020.04.002; Yadav DK, Singh A, Zhang Q, Bai X, Zhang W, Yadav RK, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut. 2021;70(4):807–9. https://doi.org/10.1136/gutjnl-2020-322072; Pazgan-Simon M, Serafińska S, Kukla M, Kucharska M, Zuwała-Jagiełło J, Buczyńska I, et al. Liver injury in patients with COVID-19 without underlying liver disease. J Clin Med. 2022;11(2):308. https://doi.org/10.3390/jcm11020308; Olry A, Meunier L, Délire B, Larrey D, Horsmans Y, Le Louët H. Drug-induced liver injury and COVID-19 infection: the rules remain the same. Drug Saf. 2020;43(7):615–17. https://doi.org/10.1007/s40264-020-00954-z; Sodeifian F, Seyedalhosseini ZS, Kian N, Eftekhari M, Najari S, Mirsaeidi M, et al. Drug-induced liver injury in COVID-19 patients: a systematic review. Front Med (Lausanne). 2021;8:731436. https://doi.org/10.3389/fmed.2021.731436; Ивашкин ВТ, Барановский АЮ, Райхельсон КЛ, Пальгова ЛК, Маевская МВ, Кондрашина ЭА и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):101–31. https://doi.org/10.22416/1382-4376-2019-29-1-101-131; Цветов ВМ, Бурашникова ИС, Сычев ДА, Поддубная ИВ. Возможность и перспективы применения препаратов из группы цитостатиков у пациентов с COVID-19 на примере циклофосфамида. Фарматека. 2021;28(1):10–3. https://doi.org/10.18565/pharmateca.2021.1.10-13; Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–34. https://doi.org/10.1007/s00204-015-1456-2; Буеверов АО, Богомолов ПО, Буеверова ЕЛ. Гепатотоксичность антибактериальных препаратов в терапевтической практике. Клиническая микробиология и антимикробная химиотерапия. 2015;17(3):207–16. EDN: UHPUXJ; deLemos AS, Ghabril M, Rockey DC, Gu J, Barnhart HX, Fontana RJ, et al. Amoxicillin-clavulanate-induced liver injury. Dig Dis Sci. 2016;61(8):2406–16. https://doi.org/10.1007/s10620-016-4121-6; Katarey D, Verma S. Drug-induced liver injury. Clin Med (Lond). 2016;16(Suppl. 6):s104-s109. https://doi.org/10.7861/clinmedicine.16-6-s104; Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–99. https://doi.org/10.1056/NEJMoa2001282; Fontana RJ, Hayashi P, Bonkovsky HL, Kleiner DE, Kochhar S, Gu J, Ghabril M. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci. 2013;58(6):1766–75. https://doi.org/10.1007/s10620-012-2553-1; Tsuzuki S, Hayakawa K, Dоi Y, Shinozaki T, Uemura Y, Matsunaga N, et al. Effectiveness of favipiravir on nonsevere, early-stage COVID-19 in Japan: a large observational study using the COVID-19 Registry Japan. Infect Dis Ther. 2022;11(3):1075–87. https://doi.org/10.1007/s40121-022-00617-9; Руженцова ТА, Чухляев ПВ, Хавкина ДА, Гарбузов АА, Плоскирева АА, Осешнюк РА и др. Эффективность и безопасность применения фавипиравира в комплексной терапии COVID-19 легкого и среднетяжелого течения. Инфекционные болезни: новости, мнения, обучение. 2020;9(4):26–38. https://doi.org/10.33029/2305-3496-2020-9-4-26-38; Bjork JA, Wallace KB. Remdesivir; molecular and functional measures of mitochondrial safety. Toxicol Appl Pharmacol. 2021;433:115783. https://doi.org/10.1016/j.taap.2021.115783; Петров ВИ, Рязанова АЮ, Привальцева НС, Некрасов ДА. Опыт применения ремдесивира для лечения новой коронавирусной инфекции. Безопасность и риск фармакотерапии. 2022;10(4):365–80. https://doi.org/10.30895/2312-7821-2022-10-4-365-380; Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Rheumatology (Oxford). 2019;58(5):849–58. https://doi.org/10.1093/rheumatology/key361; Serviddio G, Villani R, Stallone G, Scioscia G, Foschino-Barbaro MP, Lacedonia D. Tocilizumab and liver injury in patients with COVID-19. Therap Adv Gastroenterol. 2020;13:1756284820959183. https://doi.org/10.1177/1756284820959183; Ortiz GX, Lenhart G, Becker MW, Schwambach KH, Tovo CV, Blatt CR. Drug-induced liver injury and COVID-19: a review for clinical practice. World J Hepatol. 2021;13(9):1143–53. https://doi.org/10.4254/wjh.v13.i9.1143; Jorgensen SCJ, Tse CLY, Burry L, Dresser LD. Baricitinib: a review of pharmacology, safety, and emerging clinical experience in COVID-19. Pharmacotherapy. 2020;40(8):843–56. https://doi.org/10.1002/phar.2438; Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018:5253623. https://doi.org/10.1155/2018/5253623; Schrör K. Aspirin and Reye syndrome: a review of the evidence. Paediatr Drugs. 2007;9(3):195–204. https://doi.org/10.2165/00148581-200709030-00008; Dart RC, Erdman AR, Olson KR, Christianson G, Manoguerra AS, Chyka PA, et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2006;44(1):1–18. https://doi.org/10.1080/15563650500394571; Park BK, Dear JW, Antoine DJ. Paracetamol (acetaminophen) poisoning. BMJ Clin Evid. 2015;2015:2101. PMID: 26479248; Tsuda T, Tada H, Tanaka Y, Nishida N, Yoshida T, Sawada T, et al. Amiodarone-induced reversible and irreversible hepatotoxicity: two case reports. J Med Case Rep. 2018;12(1):95. https://doi.org/10.1186/s13256-018-1629-8; Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol. 2008;6(3):228–36. https://doi.org/10.2174/157016108784912019; Pelli N, Setti M, Ceppa P, Toncini C, Indiveri F. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15(8):921–4. https://doi.org/10.1097/00042737-200308000-00014; https://www.risksafety.ru/jour/article/view/396

Διαθεσιμότητα: https://www.risksafety.ru/jour/article/view/396
https://doi.org/10.30895/2312-7821-2024-396

View record from BASE

4

Academic Journal

Metabolic dysfunction-associated steatotic liver disease and drug-induced injuries: Pathogenetic aspects, treatment and prevention ; Метаболически ассоциированная жировая болезнь печени и лекарственные поражения: патогенетические аспекты, лечение и профилактика

Συγγραφείς: I. G. Pakhomova, И. Г. Пахомова

Πηγή: Meditsinskiy sovet = Medical Council; № 15 (2024); 70–78 ; Медицинский Совет; № 15 (2024); 70–78 ; 2658-5790 ; 2079-701X

Θεματικοί όροι: эссенциальные фосфолипиды, drug-induced liver damage, therapeutic tactics, prevention, essential phospholipids, лекарственные поражения печени, лечебная тактика, профилактика

Περιγραφή αρχείου: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/8574/7529; Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. https://doi.org/10.1097/hep.0000000000000323.; Райхельсон КЛ, Маевская МВ, Жаркова МС, Гречишникова ВР, Оковитый СВ, Деева ТА и др. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(2):35–44. https://doi.org/10.22416/1382-4376-2024-961.; Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(1 Suppl.):S47–S64. https://doi.org/10.1016/j.jhep.2014.12.012.; Маевская МВ, Котовская ЮВ, Ивашкин ВТ, Ткачева ОН, Трошина ЕА, Шестакова МВ и др. Национальный Консенсус для врачей по ведению взрослых пациентов с неалкогольной жировой болезнью печени и ее основными коморбидными состояниями. Терапевтический архив. 2022;94(2):216–253. https://doi.org/10.26442/00403660.2022.02.201363.; Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–654.E9. https://doi.org/10.1016/j.cgh.2014.04.014.; Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389–397.E10. https://doi.org/10.1053/j.gastro.2015.04.043.; Meyersohn NM, Mayrhofer T, Corey KE, Bittner DO, Staziaki PV, Szilveszter B et al. Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2021;19(7):1480–1488.E14. https://doi.org/10.1016/j.cgh.2020.07.030.; Ismaiel A, Jaaouani A, Leucuta DC, Popa SL, Dumitrascu DL. The Visceral Adiposity Index in Non-Alcoholic Fatty Liver Disease and Liver FibrosisSystematic Review and Meta-Analysis. Biomedicines. 2021;9(12):1890. https://doi.org/10.3390/biomedicines9121890.; Parthasarathy G, Revelo X, Malhi H. Pathogenesis of Nonalcoholic Steatohepatitis: An Overview. Hepatol Commun. 2020;4(4):478–492. https://doi.org/10.1002/hep4.1479.; Charatcharoenwitthaya P, Lindor KD, Angulo P. The spontaneous course of liver enzymes and its correlation in nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(7):1925–1931. https://doi.org/10.1007/s10620-012-2098-3.; Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy. Chin Med J (Engl). 2020;134(1):8–19. https://doi.org/10.1097/CM9.0000000000001263.; Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. https://doi.org/10.1007/s12072-017-9793-2.; Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014;109(7):950–966. https://doi.org/10.1038/ajg.2014.131.; Björnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. Semin Liver Dis. 2014;34(2):115–122. https://doi.org/10.1055/s-0034-1375953.; Буеверов АО. Лекарственные поражения печени. РМЖ. 2012;(3):107–111. Режим доступа: https://www.rmj.ru/articles/gastroenterologiya/Lekarstvennye_poragheniya_pecheni_1/.; Райхельсон КЛ, Пальгова ЛК, Кондрашина ЭА, Марченко НВ, Барановский АЮ. Лекарственные поражения печени (клинические рекомендации для врачей). СПб.: Санкт-Петербургское общество гастроэнтерологов, гепатологов и диетологов; 2017. 116 с.; Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001;14(6):611–650. https://doi.org/10.1021/tx0002583.; Ивашкин ВТ, Барановский АЮ, Райхельсон КЛ, Пальгова ЛК, Маевская МВ, Кондрашина Е А и др. Лекарственные поражения печени (клинические рекомендации для врачей). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(1):85–115. https://doi.org/10.22416/1382-4376-2019-29-1-101-131.; Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol. 2015;89(3):327–334. https://doi.org/10.1007/s00204-015-1456-2.; Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995;22(3):820–827. Available at: https://pubmed.ncbi.nlm.nih.gov/7657288/.; Andrade RJ, Lucena MI, Fernández MC, González M. Letters to the Editor. Fatal hepatitis associated with nimesulide. J Hepatol. 2000;32(1):174. https://doi.org/10.1016/s0168-8278(00)80208-1.; Stravitz RT, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis. 2003;7(2):435–451. https://doi.org/10.1016/s1089-3261(03)00027-8.; Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol. 2009;62(6):481–492. https://doi.org/10.1136/jcp.2008.058248.; Anderson N, Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006;580(23):5533–5540. https://doi.org/10.1016/j.febslet.2006.08.061.; Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(4):195–203. https://doi.org/10.1038/nrgastro.2010.21.; Begriche K, Massart J, Robin MA, Borgne-Sanchez A, Fromenty B. Druginduced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol. 2011;54(4):773–794. https://doi.org/10.1016/j.jhep.2010.11.006.; Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf. 2006;5(4):567–583. https://doi.org/10.1517/14740338.5.4.567.; Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced Liver Injury Patterns: A Clinical Review. J Clin Transl Hepatol. 2022;10(3):543–552. https://doi.org/10.14218/JCTH.2021.00271.; Gillett RC Jr, Norrell A. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity. Am Fam Physician. 2011;83(6):711–716. Available at: https://www.aafp.org/pubs/afp/issues/2011/0315/p711.html.; Chi G, Feng XX, Ru YX, Xiong T, Gao Y, Wang H et al. TLR2/4 ligand-amplified liver inflammation promotes initiation of autoimmune hepatitis due to sustained IL-6/IL-12/IL-4/IL-25 expression. Mol Immunol. 2018;99:171–181. https://doi.org/10.1016/j.molimm.2018.05.005.; Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014;40(10):1209–1222. https://doi.org/10.1111/apt.12963.; Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35(9):2139–2146. https://doi.org/10.1111/liv.12840.; Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis. Hepatology. 2017;66(5):1486–1501. https://doi.org/10.1002/hep.29302.; Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74(5):1109–1116. https://doi.org/10.1016/j.jhep.2020.11.050.; Maev IV, Samsonov AA, Lazebnik LB, Golovanova EV, Pavlov CS, Vovk EI et al. A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. Adv Ther. 2020;37(11):4627–4640. https://doi.org/10.1007/s12325-020-01493-w.; Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. https://doi.org/10.1016/j.jacc.2018.11.003.; Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. https://doi.org/10.1093/eurheartj/ehab484.; Ежов МВ, Кухарчук ВВ, Сергиенко ИВ, Алиева АС, Анциферов МБ, Аншелес АА и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471.; Smiley III WH, Khan BV, Sperling LS. Management of the statin-intolerant patient. Curr Treat Options Cardiovasc Med. 2009;11(4):263–271. https://doi.org/10.1007/s11936-009-0027-3.; Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):597–613. https://doi.org/10.1016/j.cld.2007.06.010.; Jose J. Statins and its hepatic effects: Newer data, implications, and changing recommendations. J Pharm Bioallied Sci. 2016;8(1):23–28. https://doi.org/10.4103/0975-7406.171699.; Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374–380. https://doi.org/10.1016/j.jhep.2011.07.023.; Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf. 2007;6(6):673–684. https://doi.org/10.1517/14740338.6.6.673.; Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23(3):197–213. https://doi.org/10.2165/00002018-200023030-00003.; Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–581. https://doi.org/10.1016/j.clpt.2006.09.003.; Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41(5):343–370. https://doi.org/10.2165/00003088-200241050-00003.; Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol. 2006;97(8 Suppl. 1):S77–S81. https://doi.org/10.1016/j.amjcard.2005.12.014.; Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48(2):662–669. https://doi.org/10.1002/hep.22402.; Gómez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, nonalcoholic fatty liver patients. Aliment Pharmacol Ther. 2006;23(11):1643–1647. https://doi.org/10.1111/j.1365-2036.2006.02926.x.; Vell MS, Loomba R, Krishnan A, Wangensteen KJ, Trebicka J, Creasy KT et al. Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality. JAMA Netw Open. 2023;6(6):e2320222. https://doi.org/10.1001/jamanetworkopen.2023.20222.; Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010;103(2):71–83. https://doi.org/10.1093/qjmed/hcp158.; Lemstra M, Bird Y, Nwankwo C, Rogers M, Moraros J. Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence. 2016;10:1547–1559. https://doi.org/10.2147/PPA.S103649.; Frith J, Day CP, Robinson L, Elliott C, Jones DE, Newton JL. Potential strategies to improve uptake of exercise interventions in non-alcoholic fatty liver disease. J Hepatol. 2010;52(1):112–116. https://doi.org/10.1016/j.jhep.2009.10.010.; Baratta F, Pastori D, Polimeni L, Bucci T, Ceci F, Calabrese C et al. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance. Am J Gastroenterol. 2017;112(12):1832–1839. https://doi.org/10.1038/ajg.2017.371.; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019;70(6):1222–1261. https://doi.org/10.1016/j.jhep.2019.02.014.; Gundermann KJ, Kuenker A, Kuntz E, Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643–659. https://doi.org/10.1016/s1734-1140(11)70576-x.; Ивашкин ВТ, Маевская МВ, Павлов ЧС, Тихонов ИН, Широкова ЕН, Буеверов АО и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(2):24–42. https://doi.org/10.22416/1382-4376-2016-26-2-24-42.; Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357. https://doi.org/10.1002/hep.29367.; Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Vovk EI, Shirokova EN, Starostin KM. Effectiveness of phosphatidylcholine in alleviating steatosis in patients with non-alcoholic fatty liver disease and cardiometabolic comorbidities (MANPOWER study). BMJ Open Gastroenterol. 2020;7(1):e000341. https://doi.org/10.1136/bmjgast-2019-000341.; Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019;6(1):e000307. https://doi.org/10.1136/bmjgast-2019-000307.; Кучерявый ЮА, Морозов СВ. Гепатопротекторы: рациональные аспекты применения. М.: Форте Принт; 2012. 36 с.; Лазебник ЛБ, Голованова ЕВ, Туркина СВ, Райхельсон КЛ, Оковитый СВ, Драпкина ОМ и др. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;(1):4–52. https://doi.org/10.31146/1682-8658-ecg-185-1-4-52.; Лазебник ЛБ, Голованова ЕВ, Хлынова ОВ, Алексеенко СА, Арямкина ОЛ, Бакулин ИГ и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020;(2):29–54. https://doi.org/10.31146/1682-8658-ecg-174-2-29-54.; Gurevich V, Bondarenko B, Gundermann KJ, Schumacher R, Astashkina T, Ivanov V et al. Polyunsaturated phospholipids Increase the hypoltpidernic effect of Lovastatin. Eur J Intern Med. 1997;8:13–18. Available at: https://www.researchgate.net/publication/292301430_Polyunsaturated_phospholipids_increase_the_hypolipidemic_effect_of_Lovastatin.

Διαθεσιμότητα: https://www.med-sovet.pro/jour/article/view/8574
https://doi.org/10.21518/ms2024-343

View record from BASE

5

Academic Journal

Hepatoprotective Effect of Xymedon and its Conjugate with L-ascorbic Acid during Poisoning of Mice with a Semilethal Dose of Paracetamol ; Гепатопротекторный эффект ксимедона и его конъюгата с L-аскорбиновой кислотой при отравлении мышей полулетальной дозой парацетамола

Συγγραφείς: Belyaev, G.P., Vyshtakalyuk, A.B., Parfenov, A.A., Galyametdinova, I.V., Semenov, V.E., Zobov, V.V.

Πηγή: Biomedical Chemistry: Research and Methods; Vol. 7 No. 4 (2024); e00249 ; Biomedical Chemistry: Research and Methods; Том 7 № 4 (2024); e00249 ; 2618-7531

Θεματικοί όροι: drug-induced liver injury, acetaminophen, paracetamol, hepatoprotectors, xymedon, pyrimidine derivatives, лекарственные поражения печени, ацетаминофен, парацетамол, гепатопротекторы, ксимедон, производные пиримидина

Περιγραφή αρχείου: application/pdf; text/html

Relation: http://www.bmc-rm.org/index.php/BMCRM/article/view/249/589; http://www.bmc-rm.org/index.php/BMCRM/article/view/249/610; http://www.bmc-rm.org/index.php/BMCRM/article/view/249/611

Διαθεσιμότητα: http://www.bmc-rm.org/index.php/BMCRM/article/view/249

View record from BASE

6

Academic Journal

ЛЕКАРСТВЕННЫЕ ПОРАЖЕНИЯ ПЕЧЕНИ

Συγγραφείς: Х.Умаров, Ф.

Πηγή: SO‘NGI ILMIY TADQIQOTLAR NAZARIYASI; Vol. 7 No. 6 (2024): SO‘NGI ILMIY TADQIQOTLAR NAZARIYASI; 7-12

Θεματικοί όροι: лекарственные поражения печени, действие препарата на гепатоциты, лекарственная гепатопатия, лекарственный гепатит

Περιγραφή αρχείου: application/pdf

Relation: https://bestpublication.org/index.php/sit/article/view/11924/11828; https://bestpublication.org/index.php/sit/article/view/11924

Διαθεσιμότητα: https://bestpublication.org/index.php/sit/article/view/11924

View record from BASE

7

Academic Journal

ЛЕКАРСТВЕННО-ИНДУЦИРОВАННОЕ ПОРАЖЕНИЕ ПЕЧЕНИ

Συγγραφείς: Мухаббат Мухидиновна, Саидова, Фируз Холмуродович, Умаров

Πηγή: JOURNAL OF INNOVATIONS IN SCIENTIFIC AND EDUCATIONAL RESEARCH; Vol. 6 No. 11 (2023): JOURNAL OF INNOVATIONS IN SCIENTIFIC AND EDUCATIONAL RESEARCH; 90-99

Θεματικοί όροι: лекарственные поражения печени, гепатопротекторы

Περιγραφή αρχείου: application/pdf

Relation: https://bestpublication.org/index.php/jaj/article/view/8397/8607; https://bestpublication.org/index.php/jaj/article/view/8397

Διαθεσιμότητα: https://bestpublication.org/index.php/jaj/article/view/8397

View record from BASE

8

Academic Journal

HEPATOPROTECTIVЕ EFFECT OF THE THOROUGHWAX EXTRACT IN EXPERIMENTAL TETRACYCLINE-INDUCED HEPATITIS

Πηγή: ZHurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia». :77-82

Θεματικοί όροι: experimental tetracycline-induced hepatitis, drug-induced hepatic disorders, 03 medical and health sciences, 0302 clinical medicine, thoroughwax dry extract, экстракт сухой травы володушки золотистой, экспериментальный тетрациклиновый гепатит, гепатопротекторные и детоксицирующие свойства, лекарственные поражения печени, hepatoprotective and detoxifying effect, 3. Good health

9

Academic Journal

Drug-induced liver injury associated with the use of nonsteroidal antiinflammatory drugs

Πηγή: Лекарства Украины; № 3(249) (2021); 26-30
Medicine of Ukraine; No. 3(249) (2021); 26-30
Ліки України; № 3(249) (2021); 26-30

Θεματικοί όροι: нестероїдні протизапальні препарати, nonsteroidal antiinflammatory drugs, нестероидные противовоспалительные препараты, лекарственные поражения печени, drug-induced liver injury, медикаментозні ураження печінки, 3. Good health

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: http://lu-journal.com.ua/article/view/238037

10

Academic Journal

Омский государственный медицинский университет Министерства здравоохранения России

Πηγή: Медицинский совет, Vol 0, Iss 5, Pp 70-73 (2016)

Θεματικοί όροι: лекарственные поражения печени, диагностика, лечение, адеметионин, гептор, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1328; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/e5fe8505553846bca055ad8bfcf2df4c

View record in DOAJ Full Text Finder

11

Academic Journal

Drug-induced liver disease: role of hepatoprotectors

Συγγραφείς: L. Y. Ilchenko, T. I. Korovich

Πηγή: Медицинский совет, Vol 0, Iss 10, Pp 32-37 (2013)

Θεματικοί όροι: лекарственные поражения печени, гепатотоксичность, гепатопротекторы, drug-induced liver disease, hepatotoxicity, hepatoprotectors, Medicine

Περιγραφή αρχείου: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/1120; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

Σύνδεσμος πρόσβασης: https://doaj.org/article/bebc48b8ae0c4e73905d180bd00bfaf5

View record in DOAJ Full Text Finder

12

Academic Journal

DRUG-INDUCED LIVER LESIONS AND THEIR MANAGEMENT IN THE MANIFESTATIONS OF TUBERCULOSIS

Συγγραφείς: A. V. Mordyk, O. G. Ivanova, L. A. Nagibina, S. V. Sitnikova, O. A. Marekhina

Πηγή: Туберкулез и болезни лёгких, Vol 0, Iss 9, Pp 47-53 (2015)

Θεματικοί όροι: туберкулез органов дыхания, лекарственные поражения печени, ремаксол, Diseases of the respiratory system, RC705-779

Relation: https://www.tibl-journal.com/jour/article/view/796; https://doaj.org/toc/2075-1230; https://doaj.org/toc/2542-1506; https://doaj.org/article/91e85e391f29445bb9e2b5f15284c894

Διαθεσιμότητα: https://doaj.org/article/91e85e391f29445bb9e2b5f15284c894

View record from BASE

13

Academic Journal

SUCCINIC ACID PREPARATIONS IN THE COMBINATION TREATMENT OF PATIENTS WITH TUBERCULOSIS ; ПРЕПАРАТЫ ЯНТАРНОЙ КИСЛОТЫ В КОМПЛЕКСНОМ ЛЕЧЕНИИ БОЛЬНЫХ ТУБЕРКУЛЕЗОМ

Συγγραφείς: A. V. Mordykh, O. G. Ivanova, L. A. Nagibina, S. V. Sitnikov, А. В. Мордык, О. Г. Иванова, Л. А. Нагибина, С. В. Ситникова

Πηγή: Tuberculosis and Lung Diseases; № 6 (2014); 61-65 ; Туберкулез и болезни легких; № 6 (2014); 61-65 ; 2542-1506 ; 2075-1230

Θεματικοί όροι: реамберин, adverse reactions, drug-induced liver injury, reamberine, нежелательные побочные реакции, лекарственные поражения печени

Περιγραφή αρχείου: application/pdf

Relation: https://www.tibl-journal.com/jour/article/view/93/94; Литература Афанасьев В. В. Клиническая фармакология реамберина (очерк): Пособие для врачей. - СПб., 2005. - 4 с.; Иванова Д. А. Нежелательные побочные реакции при лечении больных туберкулезом // Туб. - 2011. - № 6. - С. 60-69.; Кальф-Калиф Я. Я. О лейкоцитарном индексе интоксикации и его прогностическом значении // Врач. дело. - 1941. - № 1. - С. 31-36.; Мордык А. В. Патогенез и обоснование способов коррекции кардиотоксического действия противотуберкулезных препаратов (клинико-экспериментальное исследование): Автореф. дис. … д-ра мед. наук. - Омск, 2008. - 43 с.; Мордык А. В., Березников А. В., Конев В. П. Лекарственные поражения печени с упорным течением и недостаточным ответом на терапию: результаты ведомственной экспертизы и клинических наблюдений // Пробл. туб. - 2010. - № 4. - С. 43-47.; Оковитый С. В., Суханов Д. С., Заплутанов В. А. и др. Антигипоксанты в современной клинической практике // Клин. медицина. - 2012. - № 9. - С. 6-12.; Суханов Д. С., Виноградова Т. И., Заболотных Н. В. и др. Сравнительное изучение гепатопротективного действия ремаксола, реамберина и адеметионина при повреждении печени противотуберкулезными препаратами (экспериментальное исследование) // Антибиот. и химиотерапия. - 2011. - Т. 56, № 1-2. - С. 12-16.; Суханов Д. С., Оковитый С. В. Гепатотропные средства в терапии поражений печени противотуберкулезными препаратами: Учебное пособие. - СПб., 2012. - 64 с.; Трибунская О. В. Антигипоксант в практике противотуберкулезного стационара // Вестн. Санкт-Петербургской гос. мед. академии им. И. И. Мечникова. - 2006. - № 1. - С. 210-211.; Яковенко Э. П., Яковенко А. В., Иванов А. Н. и др. Патогенетические подходы к терапии лекарственных поражений печени // Consilium medicum (Гастроэнтерология). - 2009. - № 1. - С. 27-31.; Яковлев А. Ю. Реамберин в практике инфузионной терапии критических состояний. Практические рекомендации. - СПб., 2011. - 32 с.; Adhvaryu M. R., Reddy N. M., Vakharia B. C. Prevention of hepatotoxicity due to anti tuberculosis treatment: A novel integrative approach // World J. Gastroenterol. - 2008. - Vol. 14, № 30. - P. 1431-1446.

Διαθεσιμότητα: https://www.tibl-journal.com/jour/article/view/93
https://doi.org/10.21292/2075-1230-2014-0-6-61-65

View record from BASE

14

Academic Journal